How to Fight Your Insurance Denial for MS Treatment

Multiple sclerosis is a progressive neurological disease where every relapse, every new MRI lesion, and every month of untreated inflammation causes irreversible brain and spinal cord damage. High-efficacy disease-modifying therapies (DMTs)—such as Ocrevus, Kesimpta, Tysabri, Mavenclad, and others—can dramatically reduce relapses and slow disability progression. Yet insurers routinely deny these treatments, citing "not medically necessary," demanding step therapy through older, less effective drugs, or labeling newer options "experimental." These delays aren't administrative inconveniences—they're clinical harm. This guide will walk you through the most common denial templates, the specific clinical evidence insurers are required to respect, and concrete steps to build a winning appeal.

Why Insurers Deny MS Treatments

MS drug denials typically fall into one of five templates:

1. Step therapy / fail-first requirements

The insurer demands you try and fail older, cheaper drugs (often oral DMTs like Tecfidera, Aubagio, or injectable interferon-beta/Copaxone) before they'll approve high-efficacy therapies like Ocrevus, Kesimpta, or Tysabri—even when your neurologist recommends starting with a high-efficacy DMT due to highly active disease.

2. "Not medically necessary" for your MS subtype

Common for primary progressive MS (PPMS): the insurer claims high-efficacy DMTs aren't proven, ignoring that Ocrevus is the only FDA-approved therapy for PPMS. Or they deny escalation from platform therapies in relapsing-remitting MS (RRMS) despite documented breakthrough disease (new relapses or MRI lesions).

3. "Experimental" or "investigational" label

Frequently applied to autologous hematopoietic stem cell transplant (HSCT) for highly active MS, despite peer-reviewed evidence in JAMA (MIST trial, 2019) and multiple international registries. Also sometimes applied to off-label rituximab (Rituxan), even though it's widely used in MS based on strong clinical trial data.

4. Safety concerns overriding clinical judgment

Tysabri denials citing progressive multifocal leukoencephalopathy (PML) risk—even when your JCV antibody is negative or low-index, making PML risk negligible. Or blanket denials of Lemtrada citing autoimmune side effects without acknowledging risk-mitigation protocols.

5. Prior authorization bureaucratic loops

Requests for redundant documentation (MRI reports, EDSS scores, prior DMT records) already submitted; arbitrary requirements not found in published medical policy; demands for peer-to-peer reviews that never get scheduled. These are delay tactics, not legitimate clinical review.

The Citations Insurers Respect

When you appeal, reference these authoritative sources by name. Insurers' medical directors are required to follow national clinical guidelines and FDA labeling. Vague appeals fail; specific citations force accountability.

Clinical Practice Guidelines

American Academy of Neurology (AAN) 2018 Practice Guideline (Reaffirmed 2022)

Rae-Grant A, et al. "Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis." Neurology 2018;90(17):777-788.

Key recommendations:

• Offer DMT to patients with relapsing MS and recent clinical relapses or MRI activity.
• Switch to higher-efficacy DMT in patients with breakthrough disease (new relapses or MRI lesions) despite treatment.
• Clinicians should base DMT selection on disease activity, patient preference, safety profile, and adherence—not insurer cost considerations.

ECTRIMS/EAN Guideline 2018

Montalban X, et al. "ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis." Multiple Sclerosis Journal 2018;24(2):96-120.

Emphasizes early treatment initiation and escalation to high-efficacy DMTs for patients with highly active or rapidly evolving severe MS. Explicitly supports starting high-efficacy therapy in appropriate patients rather than mandatory step therapy.

Brain Health: Time Matters in MS (2016 Consensus)

Giovannoni G, et al. Multiple Sclerosis and Related Disorders 2016;9 Suppl 1:S5-S48.

International consensus statement: early diagnosis, early effective treatment, and proactive monitoring preserve brain volume and prevent irreversible disability. Delays in appropriate treatment accelerate neurodegeneration.

Consortium of Multiple Sclerosis Centers (CMSC) Guidelines

MRI protocol and clinical guidelines (2018, updated 2024). Establishes that MRI activity (new T2 or gadolinium-enhancing lesions) constitutes treatment failure and warrants escalation.

Pivotal Clinical Trials (Real, Not Hypothetical)

Ocrevus (ocrelizumab)

• OPERA I & II trials (Hauser S, NEJM 2017;376:221-234): superior to interferon beta-1a in RRMS, reducing annualized relapse rate by ~46%.
• ORATORIO trial (Montalban X, NEJM 2017;376:209-220): first and only therapy to show efficacy in PPMS, slowing disability progression by 24% vs. placebo.

Kesimpta (ofatumumab)

ASCLEPIOS I & II trials (Hauser SL, NEJM 2020;383:546-557): superior to teriflunomide (Aubagio) in RRMS, with 50-60% reduction in annualized relapse rate and significantly fewer new MRI lesions.

Briumvi (ublituximab)

ULTIMATE I & II trials (Steinman L, NEJM 2022;387:704-714): non-inferior to Ocrevus with faster infusion time; superior to teriflunomide.

Tysabri (natalizumab)

AFFIRM trial (Polman CH, NEJM 2006;354:899-910): ~68% reduction in annualized relapse rate vs. placebo. PML risk stratified by JCV antibody status (Plavina T, NEJM 2014;370:1869-78): negligible risk in JCV-negative patients, low risk (<1:1000) in JCV-positive patients with index <0.9 and <2 years treatment.

Rituximab (off-label for MS)

HERMES trial (Hauser SL, NEJM 2008;358:676-688); Swedish and Danish registry data (Salzer J, Neurology 2016;87:2074-2081; Granqvist M, JAMA Neurology 2018;35:940-946): rituximab as effective as other high-efficacy DMTs with favorable safety and cost profile. Widely used off-label, supported by extensive real-world evidence.

Mavenclad (cladribine)

CLARITY trial (Giovannoni G, NEJM 2010;362:416-426): superior to placebo in highly active RRMS. Oral pulsed therapy with durable efficacy.

Autologous HSCT

MIST trial (Burt RK, JAMA 2019;321:165-174): in patients with relapsing MS and inadequate response to DMTs, HSCT induced sustained remission in majority, with no relapses at 3 years in 79% vs. 0% on DMTs. Long-term follow-up (Burt RK, Neurology 2021;96:e1894-e1903) confirms durability. Not experimental—recommended for highly active MS failing DMTs per international consensus.

How to Argue Against Each Denial Reason

1. Step Therapy / Fail-First Denials

The insurer's argument:

"You must try [Tecfidera / Aubagio / interferon / Copaxone] first before we approve [Ocrevus / Kesimpta / Tysabri]."

Your counter-argument:

Step 1: Cite the AAN 2018 guideline explicitly.

The AAN guideline states DMT selection should be based on disease activity, patient factors, and shared decision-making—not a mandated sequence. Quote directly: "Clinicians should counsel patients about the potential benefits and known risks of DMTs and incorporate patient preferences into treatment decisions."

Step 2: Document highly active or rapidly evolving disease.

If you have any of the following, step therapy is inappropriate:

• ≥2 relapses in the past year
• ≥1 relapse with incomplete recovery
• Gadolinium-enhancing lesions on recent MRI (indicates active inflammation)
• ≥2 new T2 lesions on serial MRI within 12 months
• EDSS progression despite prior DMT

The ECTRIMS/EAN 2018 guideline explicitly supports starting with high-efficacy DMTs in patients with "highly active disease" or "rapidly evolving severe MS." If your neurologist checked these boxes, step therapy delays appropriate care.

Step 3: Cite the "Time Matters" consensus.

Every delay allows additional CNS damage. Giovannoni's Brain Health: Time Matters paper documents that brain volume loss in MS is front-loaded—early in disease course—and irreversible. Forcing you through a 6-12 month trial of a low-efficacy DMT while your disease progresses violates the standard of care.

Step 4: If the insurer cites cost, invoke state or federal parity laws.

Many states prohibit step therapy when the prescribing physician documents medical necessity. Check your state's step therapy reform law (e.g., California AB 2478, New York Insurance Law § 4903). Cite it in your appeal.

Concrete appeal language:

"The AAN 2018 guideline (reaffirmed 2022) does not support mandatory step therapy and explicitly states treatment choice should reflect disease activity and patient factors. I present with [highly active relapsing MS / 3 new T2 lesions / 2 Gd-enhancing lesions / relapse with incomplete recovery]. The ECTRIMS/EAN 2018 guideline supports initiation of high-efficacy DMT in this scenario. Delay contradicts the Brain Health: Time Matters consensus and risks irreversible disability."

2. "Not Medically Necessary" Denials

The insurer's argument:

"Ocrevus is not medically necessary for PPMS" or "Escalation to Kesimpta is not indicated because you haven't had a recent relapse" (ignoring MRI activity).

Your counter-argument:

For PPMS denials of Ocrevus:

Ocrevus is the only FDA-approved DMT for PPMS, based on the ORATORIO trial (NEJM 2017). The trial showed a 24% relative reduction in disability progression vs. placebo. Denying it means denying the only evidence-based treatment for PPMS. There is no alternative. Cite the FDA label directly and the ORATORIO publication.

For RRMS denials ignoring MRI activity:

The CMSC and AAN guidelines both recognize MRI activity (new T2 or gadolinium-enhancing lesions) as evidence of treatment failure, even without clinical relapses. This is called "subclinical disease activity" and predicts future disability. If your MRI shows new lesions, that is breakthrough disease warranting escalation. Quote the AAN 2018 guideline: "Clinicians should offer DMT to patients with a clinically isolated syndrome… or relapsing MS with recent clinical relapses or MRI activity."

Concrete appeal language:

"My recent MRI dated [date] demonstrates [2 new T2 lesions / 1 gadolinium-enhancing lesion], which the AAN 2018 guideline and CMSC protocols define as disease activity warranting DMT escalation. Subclinical MRI activity predicts disability progression. Denying escalation based solely on absence of clinical relapse ignores current neuroimmunology standards."

3. "Experimental" or "Investigational" Denials

The insurer's argument:

"HSCT is experimental" or "Rituximab is not FDA-approved for MS."

Your counter-argument for HSCT:

Step 1: Cite the MIST trial.

Published in JAMA 2019, not a fringe journal. The trial was NIH-funded, multicenter, and randomized. Results: no relapses in 79% of HSCT patients at 3 years vs. 0% in the DMT group. Long-term follow-up in Neurology 2021 confirmed durability with median 8-year follow-up.

Step 2: Cite international guideline support.

EBMT (European Society for Blood and Marrow Transplantation) and ASTCT (American Society for Transplantation and Cellular Therapy) have published consensus guidelines for HSCT in MS (2019, updated 2024). HSCT is recommended for highly active relapsing MS failing ≥2 high-efficacy DMTs. It is not experimental; it is a specialized but evidence-based treatment.

Step 3: Note the FDA's stance on off-label use.

The FDA does not regulate the practice of medicine. Physicians may prescribe any approved therapy for any indication when medically appropriate. HSCT using FDA-approved chemotherapy and stem cell harvest is lawful and supported by peer-reviewed evidence.

Your counter-argument for rituximab (off-label):

Step 1: Cite the HERMES trial and Swedish registries.

HERMES (NEJM 2008) showed efficacy. Swedish national registry data (Salzer Neurology 2016, Granqvist JAMA Neurology 2018) demonstrate rituximab is as effective as other high-efficacy DMTs with lower cost and favorable safety profile.

Step 2: Note widespread real-world use.

Rituximab is used in thousands of MS patients in Europe, Scandinavia, and increasingly in the U.S. It is not experimental; it is off-label supported by robust evidence.

Step 3: Cite cost.

If the insurer approves Ocrevus (same mechanism of action, anti-CD20), they cannot deny rituximab on the grounds of "lack of evidence." Rituximab is biosimilar in mechanism and cheaper.

Concrete appeal language (HSCT):

"The MIST trial (Burt RK, JAMA 2019;321:165) demonstrated superior efficacy of HSCT vs. DMTs in highly active MS, with 79% relapse-free at 3 years. EBMT/ASTCT consensus guidelines (2019) support HSCT in this scenario. This is not experimental; it is evidence-based treatment for refractory disease."

Concrete appeal language (rituximab):

"Rituximab's efficacy in MS is established by the HERMES trial (NEJM 2008), Swedish national registry data (Salzer Neurology 2016), and its approval for other neuroimmune conditions. Off-label use is lawful and medically appropriate when supported by evidence."

4. Safety-Based Denials (Tysabri PML, Lemtrada Autoimmunity)

The insurer's argument:

"Tysabri poses unacceptable PML risk" or "Lemtrada's safety profile precludes approval."

Your counter-argument for Tysabri:

Step 1: Provide JCV antibody status.

If you are JCV antibody-negative, PML risk is negligible (<1:10,000). Cite Plavina NEJM 2014: PML risk is stratified by JCV status. Negative status makes Tysabri one of the safest high-efficacy DMTs.

Step 2: If JCV-positive, cite index value and duration.

JCV-positive with index <0.9 and treatment <2 years: risk ~1:10,000. Index 0.9-1.5 and <2 years: ~1:1,000. These risks are lower than the disability risk of untreated active MS. Cite the risk stratification table from the Tysabri prescribing information.

Step 3: Note monitoring protocols.

The Tysabri TOUCH prescribing program mandates serial MRI monitoring. PML, if it occurs, is detectable early and manageable with PLEX and immunosuppression withdrawal. The insurer cannot override physician judgment on acceptable risk.

Your counter-argument for Lemtrada:

Lemtrada's autoimmune risks (thyroid disease, ITP, nephropathy) are known, disclosed, and manageable with the FDA-mandated monitoring program (monthly labs for 48 months post-treatment). These risks do not make the drug inappropriate for patients with highly active MS failing other therapies. Cite the CARE-MS trials (Lancet 2012) demonstrating superior efficacy vs. interferon, and note that the FDA approved Lemtrada with the monitoring program—acknowledging risks are acceptable when managed.

Concrete appeal language (Tysabri):

"My JCV antibody test dated [date] is negative, conferring negligible PML risk (<1:10,000 per Plavina NEJM 2014). Tysabri is appropriate and safe in this context. Blanket denial based on PML risk ignores individualized risk stratification, which is the standard of care."

5. Bureaucratic / Documentation Loop Denials

The insurer's argument:

"Additional documentation required" (despite prior submission), or no substantive denial reason given.

Your response:

Step 1: Resubmit with a cover letter listing every document enclosed, by name and date.

Example: "Enclosed: (1) MRI brain/spine dated 2/15/26 with radiology report; (2) Neurology consultation note dated 3/1/26; (3) EDSS documentation; (4) Prior DMT trial summary; (5) This appeal letter."

Step 2: Request a peer-to-peer review in writing.

Many denials evaporate when a medical director speaks with your neurologist. In your appeal, write: "I request an urgent peer-to-peer review between the plan's medical director and my treating neurologist, [name], [phone]. Per [state] Insurance Code [cite if applicable], this review must occur within [5/7/10] business days."

Step 3: Cite the plan's own medical policy.

If the insurer cited a policy number (e.g., "Aetna CPB 0264" or "Anthem CG-DRUG-87"), obtain that policy document (available online or via member services). Policies often include criteria you do meet (e.g., "documented inadequate response to prior DMT"). Quote the policy language back, showing you satisfy the criteria.

Step 4: Escalate to external review if internal appeal fails.

Under the Affordable Care Act, you have the right to external review by an independent physician not employed by the insurer. Many state insurance departments also offer assistance. Don't stop at the first denial.

What We Do

We build AI-assisted, physician-ready appeal letters for patients denied MS treatments. You provide your clinical details—MRI reports, prior DMTs, EDSS, subtype—and we generate a structured letter citing the AAN 2018 guideline, pivotal trials, and clinical factors specific to your case. The letter is formatted for your neurologist to review, sign, and submit on your behalf. We don't replace your medical team; we give them the evidence-based ammunition they need to fight bureaucratic denials efficiently. Every appeal is grounded in real guidelines and real trials—not jargon or fluff.

Sources

1. Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis. Neurology 2018;90(17):777-788. (Reaffirmed 2022.)

2. Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Multiple Sclerosis Journal 2018;24(2):96-120.

3. Giovannoni G, Butzkueven H, Dhib-Jalbut S, et al. Brain health: time matters in multiple sclerosis. Multiple Sclerosis and Related Disorders 2016;9 Suppl 1:S5-S48.

4. Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis (OPERA I and OPERA II). NEJM 2017;376(3):221-234.

5. Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis (ORATORIO). NEJM 2017;376(3):209-220.

6. Hauser SL, Bar-Or A, Cohen JA, et al. Ofatumumab versus teriflunomide in relapsing multiple sclerosis (ASCLEPIOS I and II). NEJM 2020;383(6):546-557.

7. Steinman L, Fox E, Hartung HP, et al. Ublituximab versus teriflunomide in relapsing multiple sclerosis (ULTIMATE I and II). NEJM 2022;387(8):704-714.

8. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis (HERMES). NEJM 2008;358(7):676-688.

9. Salzer J, Svenningsson R, Alping P, et al. Rituximab in multiple sclerosis: a retrospective observational study. Neurology 2016;87(20):2074-2081.

10. Granqvist M, Boremalm M, Poorghobad A, et al. Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurology 2018;75(8):940-946.

11. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis (AFFIRM). NEJM 2006;354(9):899-910.

12. Plavina T, Subramanyam M, Bloomgren G, et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. NEJM 2014;370(20):1869-1878.

13. Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis (CLARITY). NEJM 2010;362(5):416-426.

14. Burt RK, Balabanov R, Han X, et al. Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis (MIST). JAMA 2019;321(2):165-174.

15. Burt RK, Tappenden P, Muraro PA, et al. Long-term follow-up after autologous hematopoietic stem cell transplantation for multiple sclerosis. Neurology 2021;96(11):e1894-e1903.

16. Sharrack B, Saccardi R, Alexander T, et al. Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE). Bone Marrow Transplantation 2020;55(2):283-306.

17. Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial (CARE-MS II). Lancet 2012;380(9856):1829-1839.